BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts

With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.

On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target. The firm cited upcoming ACCESS I and II Phase 2b obesity trial readouts, believing they could bolster the company’s competitive position in the weight-loss drug market. The investment firm highlighted easing expectations following Eli Lilly’s recent data, which makes Structure’s results a crucial benchmark.

Meanwhile, Structure Therapeutics Inc. (NASDAQ:GPCR) reported its Q3 2025 results on November 6. The quarter saw the company reaffirm that its ongoing obesity studies remain on track for year-end. In the quarter, the company also noted progress on its oral amylin receptor agonist programs. However, research costs came out high, reaching $59 million, which the company expects to remain elevated due to upcoming trial spending. The net loss widened to $65.7 million, compared to $34 million in Q3 2024.

Structure Therapeutics Inc. (NASDAQ:GPCR) ended the quarter with a strong cash position of $799 million, which will support the company’s continued development and planned study initiations through 2026.

Structure Therapeutics Inc. (NASDAQ:GPCR), a biopharmaceutical company, develops oral small-molecule treatments for metabolic diseases.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.